Puma Biotechnology Investor Presentation — January 2021

Presented at the???????#??? Summary and conclusions ■ Neratinib is safe and tolerable in patients with advanced biliary tract cancers with somatic HER2 mutations: – Although the study did not meet its prespecified criteria for further expansion, the antitumor activity of neratini